Half way into Gedea Biotech’s NEFERTITI clinical trial of pHyph - antibiotic-free treatment of bacterial vaginosis
Lund, Sweden, September 8, 2021, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled more than 50% of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University NHS Hospitals Trust in the UK.Bacterial vaginosis is the most common vaginal infection and affects around 10-30% of women of reproductive age. It is a condition of the